Cargando…
The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
BACKGROUND: Chemotherapy and surgery have been the mainstays of epithelial ovarian cancer (EOC) treatment so far. Cellular immunotherapies such as CAR T cell therapy have recently given hope of a cure for solid tumors like EOC. However, extrinsic factors associated with the CAR T cell manufacturing...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225096/ https://www.ncbi.nlm.nih.gov/pubmed/37244991 http://dx.doi.org/10.1186/s12935-023-02948-0 |
_version_ | 1785050326005448704 |
---|---|
author | Akbari, Behnia Soltantoyeh, Tahereh Shahosseini, Zahra Yarandi, Fariba Hadjati, Jamshid Mirzaei, Hamid Reza |
author_facet | Akbari, Behnia Soltantoyeh, Tahereh Shahosseini, Zahra Yarandi, Fariba Hadjati, Jamshid Mirzaei, Hamid Reza |
author_sort | Akbari, Behnia |
collection | PubMed |
description | BACKGROUND: Chemotherapy and surgery have been the mainstays of epithelial ovarian cancer (EOC) treatment so far. Cellular immunotherapies such as CAR T cell therapy have recently given hope of a cure for solid tumors like EOC. However, extrinsic factors associated with the CAR T cell manufacturing process and/or intrinsic dysregulation of patient-derived T cells, which could be associated with cancer itself, cancer stage, and treatment regimen, may hamper the efficacy of CAR T cell therapy and promote their exhaustion or dysfunction. METHODS: To investigate the association of these factors with CAR T cell exhaustion, the frequency of T and CAR T cells expressing three immune inhibitory receptors (i.e., TIM3, PD1, A2aR) generated from T cells of EOC patients and healthy controls was measured during each stage of CAR T cell production. RESULTS: Our findings revealed that primary T cells from EOC patients show significantly elevated expression of immune inhibitory receptors, and this increase was more prominent in patients undergoing chemotherapy and those with advanced cancer. In addition, the CAR T cell manufacturing process itself was found to upregulate the expression of these inhibitory receptors and more importantly increase the population of exhausted mesoCAR T cells. CONCLUSIONS: Our observations suggest that intrinsic characteristics of patient-derived T cells and extrinsic factors in CAR T cell production protocols should be considered and properly counteracted during CAR T cell manufacturing process. In addition, mitigating the signaling of immune inhibitory receptors through pharmacological/genetic perturbation during CAR T cell manufacturing might profoundly improve CAR T cells function and their antitumor activity in EOC and other solid tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02948-0. |
format | Online Article Text |
id | pubmed-10225096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102250962023-05-29 The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer Akbari, Behnia Soltantoyeh, Tahereh Shahosseini, Zahra Yarandi, Fariba Hadjati, Jamshid Mirzaei, Hamid Reza Cancer Cell Int Research BACKGROUND: Chemotherapy and surgery have been the mainstays of epithelial ovarian cancer (EOC) treatment so far. Cellular immunotherapies such as CAR T cell therapy have recently given hope of a cure for solid tumors like EOC. However, extrinsic factors associated with the CAR T cell manufacturing process and/or intrinsic dysregulation of patient-derived T cells, which could be associated with cancer itself, cancer stage, and treatment regimen, may hamper the efficacy of CAR T cell therapy and promote their exhaustion or dysfunction. METHODS: To investigate the association of these factors with CAR T cell exhaustion, the frequency of T and CAR T cells expressing three immune inhibitory receptors (i.e., TIM3, PD1, A2aR) generated from T cells of EOC patients and healthy controls was measured during each stage of CAR T cell production. RESULTS: Our findings revealed that primary T cells from EOC patients show significantly elevated expression of immune inhibitory receptors, and this increase was more prominent in patients undergoing chemotherapy and those with advanced cancer. In addition, the CAR T cell manufacturing process itself was found to upregulate the expression of these inhibitory receptors and more importantly increase the population of exhausted mesoCAR T cells. CONCLUSIONS: Our observations suggest that intrinsic characteristics of patient-derived T cells and extrinsic factors in CAR T cell production protocols should be considered and properly counteracted during CAR T cell manufacturing process. In addition, mitigating the signaling of immune inhibitory receptors through pharmacological/genetic perturbation during CAR T cell manufacturing might profoundly improve CAR T cells function and their antitumor activity in EOC and other solid tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02948-0. BioMed Central 2023-05-27 /pmc/articles/PMC10225096/ /pubmed/37244991 http://dx.doi.org/10.1186/s12935-023-02948-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Akbari, Behnia Soltantoyeh, Tahereh Shahosseini, Zahra Yarandi, Fariba Hadjati, Jamshid Mirzaei, Hamid Reza The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer |
title | The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer |
title_full | The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer |
title_fullStr | The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer |
title_full_unstemmed | The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer |
title_short | The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer |
title_sort | inhibitory receptors pd1, tim3, and a2ar are highly expressed during mesocar t cell manufacturing in advanced human epithelial ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225096/ https://www.ncbi.nlm.nih.gov/pubmed/37244991 http://dx.doi.org/10.1186/s12935-023-02948-0 |
work_keys_str_mv | AT akbaribehnia theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT soltantoyehtahereh theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT shahosseinizahra theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT yarandifariba theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT hadjatijamshid theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT mirzaeihamidreza theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT akbaribehnia inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT soltantoyehtahereh inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT shahosseinizahra inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT yarandifariba inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT hadjatijamshid inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer AT mirzaeihamidreza inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer |